Research summary
CagriSema research
An investigational fixed combination of the long-acting amylin analog cagrilintide and the GLP-1 agonist GLP-1S.
Metabolic CombinationFixed combination (cagrilintide + semaglutide)AAsTwo co-formulated peptidesMWNot applicable (combination)CASNot applicable (combination)StatusPhase III (not yet approved)NCAANot listed
Evidence at a glance
What the research says about CagriSema
The CagriSema evidence base cited here is 3 sources — 2 clinical, 1 preclinical. Its strongest evidence is human — 2 clinical studies, most recently 2025 ("Coadministered Cagrilintide and Semaglutide 2.4 mg in Adults with Obesit…"). Regulatory status: Phase III (not yet approved).
Key findings
What the literature shows
- Fixed-ratio combination of cagrilintide (amylin analogue) + GLP-1S (GLP-1 agonist) in a once-weekly subcutaneous injection — dual complementary mechanisms targeting satiety, gastric emptying, and energy expenditure.
- REIMAGINE Phase 2/3 trials demonstrated ~25% mean body weight loss at 68 weeks, with significant improvements in HbA1c, waist circumference, and blood pressure.
- Superior to either component alone, supporting the hypothesis that combinatorial incretin/amylin signaling is more effective than any single-pathway approach.
Citations
3 peer-reviewed sources
All citations link to the original source (PubMed, journal site, or regulatory filing). Independent research database — no vendor influence on what's cited.
Clinical2 sources
Related research